Will the launch of Favipiravir mark the turnaround for Glenmark Pharma?
Posted by
www.biotecnika.org
If the drug proves to be efficacious for Covid treatment, Glenmark
will enjoy first mover advantage.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/will-the-launch-of-favipiravir-mark-the-turnaround-for-glenmark-pharma/articleshow/76498905.cms
Subscribe to:
Post Comments (Atom)
Post a Comment